{"disease":{"id":"idh1-mutation-myeloid-neoplasms","name":"idh1 mutation myeloid neoplasms"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03564821","title":"IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}